medigraphic.com

2016, Número 3

<< Anterior Siguiente >>

Rev Hematol Mex 2016; 17 (3)


Observaciones relacionadas con los métodos diagnósticos ideales en el paciente con leucemia mieloide aguda

Cruz-Santana LC, Garza-Ledezma MA, Méndez-Ramírez N, Cárdenas-Araujo D, Gómez-Almaguer D

Idioma: Español
Referencias bibliográficas: 35
Paginas: 187-194
Archivo PDF: 352.72 Kb.


RESUMEN

La leucemia mieloide aguda es un trastorno clonal heterogéneo de las células madre hematopoyéticas; en la actualidad es la leucemia aguda más común en adultos. La mediana de edad en población de raza blanca de Estados Unidos es de 67 años en el momento del diagnóstico; sin embargo, la mediana de edad en México se ha reportado entre 32 y 44 años. El diagnóstico se sospecha con los síntomas de los pacientes o con los resultados de la biometría hemática. No obstante, se necesita realizar una serie de estudios para confirmar el diagnóstico de esta enfermedad. En las últimas décadas, el inmunofenotipo por citometría de flujo, los marcadores citogenéticos y los moleculares adquirieron importancia y se convirtieron en herramientas de diagnóstico y seguimiento, así como de gran valor pronóstico en la leucemia mieloide aguda.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.

  2. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006;368:1894-1907.

  3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute. Disponible en: http://seer.cancer.gov/ statfacts/html/amyl.html

  4. Cancer Research UK. Disponible en: http://www.cancerresearchuk. org/health-professional/cancer-statistics/ statistics-by-cancer-type/leukaemia-aml#heading-Zero [Accessed June 2016].

  5. Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006;107:2099-2107.

  6. Jaime-Pérez JC, Brito-Ramirez AS, Pinzon-Uresti MA, et al. Characteristics and clinical evolution of patients with acute myeloblastic leukemia in northeast Mexico: an eightyear experience at a university hospital. Acta Haematol 2014;132:144-151.

  7. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: a real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2014;113:4179-4187.

  8. Buitrón-Santiago N, Arteaga-Ortiz L, Rosas-López A, et al. Experiencia del INCMNSZ en pacientes adultos con leucemia mieloide aguda. Cohorte 2003-2008. Rev Investig Clin 2010;62:100-108.

  9. Döhner H, Estey E, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.

  10. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951.

  11. Aguilar LB, De León RE, Pérez U, Montaño EH y col. Guía de Práctica Clínica de Diagnóstico y Tratamiento de la Leucemia Mieloide Aguda. México: Instituto Mexicano del Seguro Social, 2010.

  12. Peters JM, Ansari MQ. Multiparameter flow cytometry in the diagnosis and management of acute leukemia. Arch Pathol Lab Med 2011;135:44-54.

  13. Juaìrez-Velaìzquez R, Peìrez-Vera P. Citometriìa de flujo en la evaluacioìn de enfermedad miìnima residual en leucemia linfoblaìstica aguda. Acta Pediatr Mex 2012;33:198-206.

  14. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2009;96:4075-4083.

  15. Morrissette JJ, Bagg A. Acute myeloid leukemia: conventional cytogenetics, FISH, and moleculocentric methodologies. Clin Lab Med 2011;31:659-686.

  16. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The medical research council adult and children’s leukaemia working parties. Blood 1998;92:2322-2333.

  17. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-1320.

  18. Byrd JC, Mro K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia : results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336.

  19. Breems DA, Van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Onco. 2008;26:4791-4797.

  20. Mrózek K, Döhner H, Bloomfield CD. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol 2007;14:106-114.

  21. Lazarevic V, Hörstedt AS, Johansson B, et al. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer J. 2014;4:88. doi: 10.1038/bcj.2014.10.

  22. Wahlin A, Markevärn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukemia. Br J Haematol 2001;115:25- 33.

  23. Fröhling S, Kayser S, Mayer C, et al. AML Study Group Ulm. Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia. Haematologica 2005;90:194-199.

  24. Tavor S, Rothman R, Golan T, et al. Predictive value of TP53 fluorescence in situ hybridization in cytogenetic subgroups of acute myeloid leukemia. Leuk Lymphoma 2011;52:642-647.

  25. Vance GH, Kim H, Hicks GA, et al. Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). Leuk Res 2007;31:605-609.

  26. Khaled S, Al-Malki M, Marcucci G. Acute myeloid leukemia: biologic, prognostic and therapeutic insights. Oncology 2016;30:318-329.

  27. Döhner K, Döhner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008;93:976-982.

  28. Mrózek K, Prior TW, Edwards C, et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2001;19:2482-2492.

  29. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and geneexpression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-448.

  30. Cuervo-Sierra J, Jaime-Pérez JC, Gómez-Almaguer D. Mutaciones del módulo FLT3 en leucemia aguda mieloblástica. Rev Hematol Mex 2012;13:177-184.

  31. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006;108:3654-3661.

  32. Cuervo-Sierra J, Jaime-Pérez JC, Martínez-Hernández RA, et al. Prevalence and clinical significance of FLT3 mutation status in acute myeloid leukemia patients in two Latin American countries: a multicenter study. Arch Med Res 2016.

  33. Lucena-Araujo AR, Souza DL, Morato de Oliveira F, et al. Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemia. Ann Hematol 2010;89:225-228.

  34. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.

  35. Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007;110:1262-1270.




2020     |     www.medigraphic.com